The team recently developed a fully automated method, called PROSS, for dramatically improving the stability and expressibility of recalcitrant proteins and methods for improving affinity, specificity, and catalytic rates in antibodies and enzymes. As a postdoc with David Baker, Dr. Fleishman developed the first accurate methods for designing protein binders, culminating in the design of broad-specificity influenza inhibitors. The team currently focuses on automated design of repertoires of conventional and camelid antibodies for one-shot isolation of high-affinity, site-targeted binders and inhibitors.